Small Molecules
13 September 2018
M3 Biotechnology begins testing of its novel therapy NDX-1017 in individuals with Alzheimer’s disease or mild cognitive impairment13 September 2018
Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with Classic Congenital Adrenal Hyperplasia13 September 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine13 September 2018
FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals13 September 2018
Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 140413 September 2018
Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient13 September 2018
Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis12 September 2018
FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain12 September 2018
KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug12 September 2018
ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)12 September 2018
Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis10 September 2018
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer10 September 2018
Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites8 September 2018
European Commission Expands Labelling for Janssen’s INVOKANA® and VOKANAMET® to Include Positive Data on Cardiovascular Outcomes8 September 2018
Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness7 September 2018
ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)6 September 2018
Advicenne Announces FDA Clearance of IND to Commence Pivotal Phase 3 Trial of ADV7103 for Distal Renal Tubular AcidosisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports